ANGIOTECH PHARMACEUTICALS IN
WKN: 931538 / ISIN: CA0349181028Angiotech - Reboundkandidat?
| eröffnet am: | 23.09.08 20:34 von: | martin30sm |
| neuester Beitrag: | 12.01.11 13:47 von: | Chalifmann3 |
| Anzahl Beiträge: | 29 | |
| Leser gesamt: | 5799 | |
| davon Heute: | 3 | |
bewertet mit 3 Sternen |
||
|
|
||
23.09.08 20:34
#1
martin30sm
Angiotech - Reboundkandidat?
Hat jemand eine Ahnung warum Angiotech in den letzten Tagen so fällt?
Könnte ein interessanter Reboundkandidat werden.
Bitte um Eure Meinungen!
Könnte ein interessanter Reboundkandidat werden.
Bitte um Eure Meinungen!
Angehängte Grafik:
p_3_.gif (verkleinert auf 68%)
p_3_.gif (verkleinert auf 68%)
3 Postings ausgeblendet.
29.01.09 21:04
#15
martin30sm
NEWS!
ANGIOTECH’S CORPORATE PARTNER, BOSTON SCIENTIFIC, ANNOUNCES JAPANESE
APPROVAL FOR TAXUS® LIBERTÉ® DRUG-ELUTING STENT SYSTEM
VANCOUVER, BC, January 29, 2009 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a
global specialty pharmaceutical and medical device company, today announced that its corporate partner,
Boston Scientific Corporation (NYSE: BSX), has received approval from the Japanese Ministry of Health,
Labor and Welfare (MHLW) to market its TAXUS® Liberté® paclitaxel-eluting coronary stent system.
Boston Scientific plans to launch the product in Japan once reimbursement approval is granted. The
TAXUS Liberté was approved by the FDA in October 2008 and was launched in Europe and several other
international markets in 2005.
“The TAXUS Liberté stent is the latest advance in drug-eluting stent technology for Japan,” said Donald
Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. “Its safety and efficacy have been
well demonstrated in multiple clinical studies and years of clinical use.”
“We are pleased to see the approval of TAXUS Liberté in Japan as it demonstrates our partner’s
commitment to expanding its international acceptance,” said Dr. William Hunter, President and CEO of
Angiotech. “Japanese patients and their families struggling with coronary artery disease should soon be
able to benefit from this proven technology.”
TAXUS Liberté is the only second-generation drug-eluting stent approved for use in Japan. The TAXUS
Liberté stent will replace the TAXUS Express2TM stent, marketed in Japan since May 2007. Significant
design improvements over the first-generation stent include thinner struts and a more uniform stent
geometry.
Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements
containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects”
and similar expressions, constitute “forward-looking statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian
securities laws. All such statements are made pursuant to the “safe harbor” provisions of applicable securities
legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives
and priorities for the fourth quarter of 2008 and beyond, our strategies or future actions, our targets, expectations for
our financial condition and the results of, or outlook for, our operations, research, development, product and drug
development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that
may cause the actual results, events or developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these forward-looking statements and include,
among others, the following: general economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our existing products or our ability to develop
and commercialize future products; competition; existing governmental regulations and changes in, or the failure to
comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our
technology and products; the requirement for substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect
performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete prePage
2 of 2
clinical and clinical development of our products; changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and
enforce timely patent and other intellectual property protection for our technology and products; the ability to enter
into, and to maintain, corporate alliances relating to the development and commercialization of our technology and
products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell
our products; the continued availability of capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission (“SEC”) and applicable Canadian regulatory authorities.
For a more thorough discussion of the risks associated with our business, see the “Risk Factors” section in our annual
report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three
months ended September 30, 2008 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or developments.
©2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
Boston Scientific Corporation acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to certain peripheral vascular and non-vascular
products.
TAXUS® Liberté and Express2TM are registered trademarks of Boston Scientific Corporation.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions
for diseases or complications associated with medical device implants, surgical interventions and acute
injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at
www.angiotech.com.
FOR ADDITIONAL INFORMATION:
DeDe Sheel, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(415) 293-4412
dede.sheel@fdashtonpartners.com
APPROVAL FOR TAXUS® LIBERTÉ® DRUG-ELUTING STENT SYSTEM
VANCOUVER, BC, January 29, 2009 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a
global specialty pharmaceutical and medical device company, today announced that its corporate partner,
Boston Scientific Corporation (NYSE: BSX), has received approval from the Japanese Ministry of Health,
Labor and Welfare (MHLW) to market its TAXUS® Liberté® paclitaxel-eluting coronary stent system.
Boston Scientific plans to launch the product in Japan once reimbursement approval is granted. The
TAXUS Liberté was approved by the FDA in October 2008 and was launched in Europe and several other
international markets in 2005.
“The TAXUS Liberté stent is the latest advance in drug-eluting stent technology for Japan,” said Donald
Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. “Its safety and efficacy have been
well demonstrated in multiple clinical studies and years of clinical use.”
“We are pleased to see the approval of TAXUS Liberté in Japan as it demonstrates our partner’s
commitment to expanding its international acceptance,” said Dr. William Hunter, President and CEO of
Angiotech. “Japanese patients and their families struggling with coronary artery disease should soon be
able to benefit from this proven technology.”
TAXUS Liberté is the only second-generation drug-eluting stent approved for use in Japan. The TAXUS
Liberté stent will replace the TAXUS Express2TM stent, marketed in Japan since May 2007. Significant
design improvements over the first-generation stent include thinner struts and a more uniform stent
geometry.
Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements
containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects”
and similar expressions, constitute “forward-looking statements” within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian
securities laws. All such statements are made pursuant to the “safe harbor” provisions of applicable securities
legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives
and priorities for the fourth quarter of 2008 and beyond, our strategies or future actions, our targets, expectations for
our financial condition and the results of, or outlook for, our operations, research, development, product and drug
development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that
may cause the actual results, events or developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these forward-looking statements and include,
among others, the following: general economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our existing products or our ability to develop
and commercialize future products; competition; existing governmental regulations and changes in, or the failure to
comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our
technology and products; the requirement for substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect
performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete prePage
2 of 2
clinical and clinical development of our products; changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and
enforce timely patent and other intellectual property protection for our technology and products; the ability to enter
into, and to maintain, corporate alliances relating to the development and commercialization of our technology and
products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell
our products; the continued availability of capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission (“SEC”) and applicable Canadian regulatory authorities.
For a more thorough discussion of the risks associated with our business, see the “Risk Factors” section in our annual
report for the year ended December 31, 2007 filed with the SEC on Form 40-F and our quarterly report for the three
months ended September 30, 2008 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or developments.
©2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
Boston Scientific Corporation acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to certain peripheral vascular and non-vascular
products.
TAXUS® Liberté and Express2TM are registered trademarks of Boston Scientific Corporation.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions
for diseases or complications associated with medical device implants, surgical interventions and acute
injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at
www.angiotech.com.
FOR ADDITIONAL INFORMATION:
DeDe Sheel, Investor Relations and Corporate Communications
Angiotech Pharmaceuticals, Inc.
(415) 293-4412
dede.sheel@fdashtonpartners.com
31.03.09 22:07
#18
martin30sm
News
Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
VANCOUVER, March 31 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced it has completed an Amended and Restated Distribution and License Agreement with its partner Baxter International Inc. (Baxter). As consideration for the Amended and Restated Distribution and License Agreement, Angiotech will receive $25 million.
Angiotech and Baxter initially entered into a Distribution and License Agreement in 2003 relating to certain intellectual property for Angiotech's COSEAL(R) surgical sealant. The Distribution and License Agreement entitled Baxter to market and sell COSEAL worldwide (excluding Japan), from which Angiotech has derived royalty revenue from Baxter. The Distribution and License Agreement also gave Baxter an option for distribution rights in Japan.
As a result of this transaction, Baxter will obtain worldwide rights to COSEAL and certain additional fields of use for COSEAL, and expanded worldwide rights to COSEAL derivatives. Baxter will owe no further royalty or milestone obligations to Angiotech relating to the existing formulation of COSEAL or any future products under the terms of the Amended and Restated Distribution and License Agreement.
Forward Looking Statements
--------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
SOURCE Angiotech Pharmaceuticals, Inc.
VANCOUVER, March 31 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced it has completed an Amended and Restated Distribution and License Agreement with its partner Baxter International Inc. (Baxter). As consideration for the Amended and Restated Distribution and License Agreement, Angiotech will receive $25 million.
Angiotech and Baxter initially entered into a Distribution and License Agreement in 2003 relating to certain intellectual property for Angiotech's COSEAL(R) surgical sealant. The Distribution and License Agreement entitled Baxter to market and sell COSEAL worldwide (excluding Japan), from which Angiotech has derived royalty revenue from Baxter. The Distribution and License Agreement also gave Baxter an option for distribution rights in Japan.
As a result of this transaction, Baxter will obtain worldwide rights to COSEAL and certain additional fields of use for COSEAL, and expanded worldwide rights to COSEAL derivatives. Baxter will owe no further royalty or milestone obligations to Angiotech relating to the existing formulation of COSEAL or any future products under the terms of the Amended and Restated Distribution and License Agreement.
Forward Looking Statements
--------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
SOURCE Angiotech Pharmaceuticals, Inc.
11.05.09 18:28
#20
0815ax
06.05.09
http://www.thestreet.com/_yahoo/story/10497064/1/...REE&cm_ite=NA
Which insiders are selling and buying chunks of stocks?
Below are lists of the top 10 open-market insider purchases and sales filed at the Securities and Exchange Commission Thursday as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms' shares, and here is how many of them are voting their wallets!
Company Name (Ticker) - Filer Name - Title(s) - Shares Bought - Dollar Value
Angiotech Pharmaceuticals (ANPI) - Hunter William L - CEO,PR,DIR - 455,313 - $246,055
...(weiter siehe LINK)
Which insiders are selling and buying chunks of stocks?
Below are lists of the top 10 open-market insider purchases and sales filed at the Securities and Exchange Commission Thursday as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms' shares, and here is how many of them are voting their wallets!
Company Name (Ticker) - Filer Name - Title(s) - Shares Bought - Dollar Value
Angiotech Pharmaceuticals (ANPI) - Hunter William L - CEO,PR,DIR - 455,313 - $246,055
...(weiter siehe LINK)
28.09.10 07:54
#23
Heffalump
Dazu News vom Samstag
http://finance.yahoo.com/news/...prnews-2827796061.html?x=0&.v=24
10.01.11 18:38
#26
Chalifmann3
hi Martin
du "Glückspilz" !
Wenn ich flüssig wäre gerade,hätte ich auch ....... aber ich muss damit bis Februar warten,übrigens hast du den letzten 8-K von angiotech gelesen ? Ich kann darin jedenfalls nichts entdecken,was eine akute Gefährdung der Gesellschft bedeuten würde ....
MFG
Chali
P.S. Aktiengirl,auch noch dabei ?
Wenn ich flüssig wäre gerade,hätte ich auch ....... aber ich muss damit bis Februar warten,übrigens hast du den letzten 8-K von angiotech gelesen ? Ich kann darin jedenfalls nichts entdecken,was eine akute Gefährdung der Gesellschft bedeuten würde ....
MFG
Chali
P.S. Aktiengirl,auch noch dabei ?
10.01.11 19:24
#27
Inkmarker
Delisting von der NASDAQ
ANGIOTECH PHARMACEUTICALS ANNOUNCES NOTICE OF DELISTING FROM THE NASDAQ STOCK MARKET
VANCOUVER, Jan. 5 /PRNewswire/ - On January 4, 2011, Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") received a notice from The Nasdaq Stock Market ("Nasdaq") stating Angiotech has not regained compliance with Nasdaq's Listing Rule 5450(a)(1) within the 180 calendar day grace period ending January 3, 2011. Nasdaq's notice indicates Angiotech's common shares will be delisted on January 13, 2011. The Nasdaq rules provide for an appeal of the above decision by requesting a hearing in accordance with appropriate procedures as outlined by the Company Guide. Angiotech will not request a hearing. Angiotech's common shares will still be tradable on the Toronto Stock Exchange under the trading symbol "ANP".
Forward-Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2009 filed with the SEC on Form 10-K, as amended, and our quarterly report for the 3rd quarter of 2010 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
©2010 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
SOURCE Angiotech Pharmaceuticals, Inc.
Read more: http://www.nasdaq.com/aspx/...000PR_NEWS_USPRX____TO784#ixzz1AerjAbCZ
VANCOUVER, Jan. 5 /PRNewswire/ - On January 4, 2011, Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") received a notice from The Nasdaq Stock Market ("Nasdaq") stating Angiotech has not regained compliance with Nasdaq's Listing Rule 5450(a)(1) within the 180 calendar day grace period ending January 3, 2011. Nasdaq's notice indicates Angiotech's common shares will be delisted on January 13, 2011. The Nasdaq rules provide for an appeal of the above decision by requesting a hearing in accordance with appropriate procedures as outlined by the Company Guide. Angiotech will not request a hearing. Angiotech's common shares will still be tradable on the Toronto Stock Exchange under the trading symbol "ANP".
Forward-Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2009 filed with the SEC on Form 10-K, as amended, and our quarterly report for the 3rd quarter of 2010 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.
©2010 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
SOURCE Angiotech Pharmaceuticals, Inc.
Read more: http://www.nasdaq.com/aspx/...000PR_NEWS_USPRX____TO784#ixzz1AerjAbCZ
12.01.11 13:46
#28
Chalifmann3
Aktuelles
Will Quill help Angiotech survive 2011?
Posted by Cantech • January 6, 2011 • Printer-friendly
Share this post: Tweet | Facebook | StumbleUpon | Digg | Delicious
The prospect of losing their NASDAQ listing has hung over Angiotech Pharmaceuticals for a long time. Shares of the once high-flying Vancouver medical device company have been slipping for years, from a meteoric high of $36.95 on February 6th, 2004 to mere pennies today. While the delisting, which will happen on January 13th, was a foregone conclusion as the NASDAQ requires a $1 minimum bid price, other issues around Angiotech are far less certain.
Heading into 2011, Angiotech's financial health might be described as dicey. On Oct. 1, 2010, the company announced that it had not made the $9.7-million interest payment due to the holders of its 7.75-per-cent senior subordinated notes. And Angiotech may be running out of ways to deal with its financial problems; the company's cash and short term investments position has been sliced nearly in half in less than a year, from $57.32 for the quarter ended December 31st, 2009 to $31.31 million as of September 30th, 2010.
At the core of Angiotech's problems is its dependence on its royalty revenue derived from one partner, Boston Scientific. In Q3 of 2010, Angiotech royalty revenue from sales of its Taxus stent systems faced increased competition in the US. The Company saw a whopping 56% decrease, compared with the third quarter of 2009.
While some investors may fear that the loss of the NASDAQ listing and low share price may irreparably harm Angiotech by impairing its ability to raise capital, the company is providing at least a glimmer of hope. Q3 Sales of the company's proprietary medical products were $17.3-million, or 33 per cent of total product sales.
The fight for survival in the face of declining royalty payments may seem like a lopsided one, but Angiotech management believes it has a secret weapon in Quill, a knotless tissue-closure device it acquired the rights to in 2006. In at least one independent study Quill has shown to 50% reduction in operative time, a significant number in a market that Angiotech estimates is worth US $1.7 billion.
With a share price slide that led to a NASDAQ delisting, declining royalty revenues, and the announcement of a lawsuit from former shareholders, 2010 is a year that Angiotech would probably like to forget. If 2011 is to see a resurgence in the price of Angiotech's shares, Quill will almost certainly need to begin to realize its commercial potential. It is worth noting that in the company's Q3 MD&A, two reasons are given for the increased losses "a reduction in royalty revenue from BSC's sales of paclitaxtel-eluting coronary stent systems" and "an increase in selling, general and administrative costs...primarily resulting from the addition of sales and marketing staff to support our Quill Knotless Tissue-Closure Device product line." Those shareholders who still hold Angiotech on the TSX after January 13th hope the latter was money well spent.
MFG
Chali
Posted by Cantech • January 6, 2011 • Printer-friendly
Share this post: Tweet | Facebook | StumbleUpon | Digg | Delicious
The prospect of losing their NASDAQ listing has hung over Angiotech Pharmaceuticals for a long time. Shares of the once high-flying Vancouver medical device company have been slipping for years, from a meteoric high of $36.95 on February 6th, 2004 to mere pennies today. While the delisting, which will happen on January 13th, was a foregone conclusion as the NASDAQ requires a $1 minimum bid price, other issues around Angiotech are far less certain.
Heading into 2011, Angiotech's financial health might be described as dicey. On Oct. 1, 2010, the company announced that it had not made the $9.7-million interest payment due to the holders of its 7.75-per-cent senior subordinated notes. And Angiotech may be running out of ways to deal with its financial problems; the company's cash and short term investments position has been sliced nearly in half in less than a year, from $57.32 for the quarter ended December 31st, 2009 to $31.31 million as of September 30th, 2010.
At the core of Angiotech's problems is its dependence on its royalty revenue derived from one partner, Boston Scientific. In Q3 of 2010, Angiotech royalty revenue from sales of its Taxus stent systems faced increased competition in the US. The Company saw a whopping 56% decrease, compared with the third quarter of 2009.
While some investors may fear that the loss of the NASDAQ listing and low share price may irreparably harm Angiotech by impairing its ability to raise capital, the company is providing at least a glimmer of hope. Q3 Sales of the company's proprietary medical products were $17.3-million, or 33 per cent of total product sales.
The fight for survival in the face of declining royalty payments may seem like a lopsided one, but Angiotech management believes it has a secret weapon in Quill, a knotless tissue-closure device it acquired the rights to in 2006. In at least one independent study Quill has shown to 50% reduction in operative time, a significant number in a market that Angiotech estimates is worth US $1.7 billion.
With a share price slide that led to a NASDAQ delisting, declining royalty revenues, and the announcement of a lawsuit from former shareholders, 2010 is a year that Angiotech would probably like to forget. If 2011 is to see a resurgence in the price of Angiotech's shares, Quill will almost certainly need to begin to realize its commercial potential. It is worth noting that in the company's Q3 MD&A, two reasons are given for the increased losses "a reduction in royalty revenue from BSC's sales of paclitaxtel-eluting coronary stent systems" and "an increase in selling, general and administrative costs...primarily resulting from the addition of sales and marketing staff to support our Quill Knotless Tissue-Closure Device product line." Those shareholders who still hold Angiotech on the TSX after January 13th hope the latter was money well spent.
MFG
Chali